Friday, 29 March 2024


Glenmark receives ANDA approval for Ranolazine Extended-Release Tablets

09 July 2019 | News

It is a generic version of Ranexa® Extended-Release Tablets, 500 mg and 1,000 mg, of Gilead Sciences, Inc.

Glenmark Pharmaceuticals Inc. has been granted final approval by the United States Food & Drug Administration for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg, a generic version of Ranexa® Extended-Release Tablets, 500 mg and 1,000 mg, of Gilead Sciences, Inc.

According to IQVIATM sales data for the 12 month period ending May 2019, the Ranexa® Extended-Release Tablets, 500 mg and 1,000 mg market2 achieved annual sales of approximately $929.0 million.

Glenmark’s current portfolio consists of 158 products authorized for distribution in the U.S. marketplace and 57 ANDA’s pending approval with the USFDA.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account